Autopsy report · NCT03426345

Study to Evaluate the Safety and Efficacy of Relamorelin in Participants With Diabetic Gastroparesis Study 02

“The Relamorelin program is being terminated solely based on a business decision”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 2 years 5 months before it stopped.
• 311 participants enrolled.
• Results were posted on the registry 1 year 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Allergan

Sponsor type

Industry

Conditions

Gastroparesis; Diabetes Mellitus

Interventions

Placebo; Relamorelin

Participants

311

Sites

240

Countries

Argentina, Austria, Belgium, Brazil, Canada, Colombia, Denmark, Germany, Hungary, Latvia, Mexico, Russia and more

Trials that died the same way

• Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
  “Business decision to stop the program.” (62% match in meaning)
• A Study to Evaluate the Efficacy and Safety of Abiprubart in Participants With Sjögren's Disease
  “Terminated due to strategic business decision.” (56% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.